CD40-Directed SEA-CD40 Combo Denotes Antitumor ...
The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab showed a 44% ORR in metastatic PDAC patients, with tolerable AEs and evidence of immune activation, suggesting potential for immunotherapy in pancreas cancer treatment.
Related Clinical Trials
Reference News
CD40-Directed SEA-CD40 Combo Denotes Antitumor ...
The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab showed a 44% ORR in metastatic PDAC patients, with tolerable AEs and evidence of immune activation, suggesting potential for immunotherapy in pancreas cancer treatment.